Table 3 Logistic regression analysis and additional predictive value of the model including neutrophil elastase (NE) and proteinase 3 (PR3) concentrations for unfavorable outcome (mRS > 2) at 3 months in patients received IV recombinant tissue plasminogen activator (rtPA) treatment (n = 119)

Logistic regression

 R² (Cox & snell)

0.249

0.346

 Age

OR = 0.994 (0.939–1.053), p = 0.843

OR = 1.018 (0.959–1.080), p = 0.558

 Sex (male)

OR = 2.382 (0.513–11.053), p = 0.268

OR = 3.200 (0.588–17.425), p = 0.179

 Onset-to-treatment time

OR = 0.706 (0.447 -1.116), p = 0.137

OR = 0.656 (0.373–1.154), p = 0.144

 Admission NIHSS score

OR = 1.208 (1.064–1.371), p = 0.004^†

OR = 1.313 (1.108–1.556), p = 0.002^†

 Atrial fibrillation

OR = 11.771 (1.981–69.947), p = 0.007^†

OR = 18.824 (2.537–139.662), p = 0.004^†

 Serum glucose

OR = 1.159 (1.015–1.324), p = 0.030^†

OR = 1.227 (1.049–1.435), p = 0.010^†

 Neutrophil-to-lymphocyte ratio

OR = 1.097 (0.891–1.349), p = 0.384

OR = 1.118 (0.896–1.395), p = 0.324

 Neutrophil elastase > 177.22 ng/mL

Ref.

OR = 8.931 (2.330–34.238), p = 0.001^†

 Proteinase 3 > 388.77 ng/mL

Ref.

OR = 4.275 (1.045–17.491), p = 0.043^†

ROC curve

 AUC, %

84.6

89.9

 p value

Ref.

0.082

IDI index, %

 Total IDI

–

18.1 (7.7, 28.5)

 p value

Ref.

< 0.001

NRI index, %

 Categorical NRI

–

30.1 (5.3, 55.0)

 p value

Ref.

0.017

 Continuous NRI

–

91.8 (51.1, 132.6)

 p value

Ref.

< 0.001